Voloridge Investment Management’s Vaxcyte PCVX Stock Holding History

Voloridge Investment Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-519,734	Closed	-$18.7M	–	1312
2025 Q3	$18.7M	Sell	519,734 -113,470	-18%	-$3.76M	0.06%	360
2025 Q2	$20.6M	Buy	+633,204	New	+$20.8M	0.08%	314
2024 Q4	–	Sell	-224,446	Closed	-$25.6M	–	1323
2024 Q3	$25.6M	Buy	+224,446	New	+$20.2M	0.09%	315
2023 Q3	–	Sell	-40,764	Closed	-$2.04M	–	1552
2023 Q2	$2.04M	Sell	40,764 -194,817	-83%	-$9.23M	0.01%	980
2023 Q1	$8.83M	Sell	235,581 -15,605	-6%	-$662K	0.04%	483
2022 Q4	$12M	Buy	+251,186	New	+$9.86M	0.07%	383
2022 Q3	–	Sell	-12,475	Closed	-$271K	–	1575
2022 Q2	$271K	Buy	+12,475	New	+$289K	﹤0.01%	1358
2021 Q3	–	Sell	-70,341	Closed	-$1.58M	–	1807
2021 Q2	$1.58M	Buy	70,341 +21,095	+43%	+$432K	0.01%	1079
2021 Q1	$973K	Buy	+49,246	New	+$1.24M	0.01%	1026

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Voloridge Investment Management's PCVX Position: Q4 2025 in Review

Voloridge Investment Management sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 519,734 shares — an estimated $18.7M sold.

Voloridge Investment Management first reported a position in PCVX in Q1 2021 and held it in 9 quarters. The position peaked at $25.6M in Q3 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Voloridge Investment Management reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Voloridge Investment Management sold 519,734 Vaxcyte shares in Q4 2025, an estimated $18.7M.
Voloridge Investment Management first reported a position in Vaxcyte in Q1 2021 and held it in 9 quarters.
Voloridge Investment Management's Vaxcyte position peaked at $25.6M in Q3 2024.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Voloridge Investment Management's 13F filing for Q4 2025, filed 17 Feb 2026.